Imperial College London

Professor Omar Usmani

Faculty of MedicineNational Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8051o.usmani

 
 
//

Location

 

Asthma LabSouth BlockRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Verbanck:2020:10.1016/j.ejpb.2020.04.019,
author = {Verbanck, S and Biddiscombe, MF and Usmani, OS},
doi = {10.1016/j.ejpb.2020.04.019},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
pages = {18--22},
title = {Inhaled aerosol dose distribution between proximal bronchi and lung periphery},
url = {http://dx.doi.org/10.1016/j.ejpb.2020.04.019},
volume = {152},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Modern inhaled drug discovery programs assess dose delivery to proximal and distal airways using rudimentary imaging indices, where relative deposition is estimated by generically defined 'central' and 'peripheral' lung regions. Utilizing recent data linking the proximal airway topology to a characteristic pattern of aerosol lung deposition, we provide a direct measure of dose distribution between the proximal bronchi and the distal lung. We analyzed scintigraphic lung images of twelve asthma patients following inhalation of 1.5-, 3- and 6-µm monodisperse drug particles at breathing flows of 30- and 60-L/min. We explicitly used the central hot-spots associated with each patient's specific bronchial topology to obtain a direct measure of aerosol deposition in the proximal bronchi, rather than applying standard templates of lung boundaries. Maximum deposition in the central bronchi (as % of lung deposition) was 52±10(SD)% (6µm;60L/min). Minimum central deposition was 17±2(SD)% (1.5µm;30L/min) where the 83% aerosol 'escaping' deposition in the central bronchi reached 75±17(SD)% of the lung area that could be reached by Krypton gas. For all particle sizes, hot-spots appeared in the same patient-specific central airway location, with greatest intensity at 60L/min. For a range of respirable aerosol sizes and breathing flows, we have quantified deposited dose in the proximal bronchi and their distal lung reach, constituting a platform to support therapeutic inhaled aerosol drug development.
AU - Verbanck,S
AU - Biddiscombe,MF
AU - Usmani,OS
DO - 10.1016/j.ejpb.2020.04.019
EP - 22
PY - 2020///
SN - 0939-6411
SP - 18
TI - Inhaled aerosol dose distribution between proximal bronchi and lung periphery
T2 - European Journal of Pharmaceutics and Biopharmaceutics
UR - http://dx.doi.org/10.1016/j.ejpb.2020.04.019
UR - https://www.ncbi.nlm.nih.gov/pubmed/32361031
UR - http://hdl.handle.net/10044/1/79859
VL - 152
ER -